Some recent studies evaluated the role of fluorine-18 fluorodeoxyglucose (2-[ 18 F]FDG) as a radiopharmaceutical for positron emission tomography/computed tomography (PET/CT) imaging in patients with Coronavirus Disease (COVID-19). This article aims to perform a systematic review in this setting. A comprehensive computer literature search in PubMed/MEDLINE and Cochrane library databases regarding the role of 2-[ 18 F]FDG PET/CT in patients with COVID-19 was carried out. This combination of key words was used: (A) “PET” OR “positron emission tomography” AND (B) “COVID” OR “SARS”. Only pertinent original articles were selected; case reports and very small case series were excluded. We have selected 11 original studies of 2-[ 18 F]FDG PET/CT in patients with COVID-19. Evidence-based data showed first preliminary applications of this diagnostic tool in this clinical setting, with particular regard to the incidental detection of interstitial pneumonia suspected for COVID-19. To date, according to evidence-based data, 2-[ 18 F]FDG PET/CT cannot substitute or integrate high-resolution CT to diagnose suspicious COVID-19 or for disease monitoring, but it can only be useful to incidentally detect suspicious COVID-19 lesions in patients performing this imaging method for standard oncological and non-oncological indications. Published data about the possible role of 2-[ 18 F]FDG PET/CT in patients with COVID-19 are increasing, but larger studies are warranted.
【저자키워드】 COVID-19, SARS-CoV-2, Infection, systematic review, pet, FDG, fluorodeoxyglucose, 【초록키워드】 diagnostic, tomography, database, Case report, Patient, interstitial pneumonia, disease, diagnose, Combination, PET/CT, lesion, indications, clinical setting, article, High-resolution CT, selected, detect, carried, evaluated, case sery, patients with COVID-19, suspicious COVID-19, were excluded, 【제목키워드】 review, PET/CT, role, Radiopharmaceutical,